EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	208452	ANDA	Mylan Pharmaceuticals Inc.	0378-5440-93	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-5440-93)	2025-05-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

The demand for antiviral medications, particularly those used in HIV therapy, has surged globally, emphasizing the importance of a reliable supply chain. Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate (TDF) serve as critical components in combination therapies such as the widely prescribed Antiretroviral Therapy (ART) regimens. Ensuring access to high-quality suppliers of these active pharmaceutical ingredients (APIs) and finished products is vital for manufacturers, healthcare providers, and policymakers.

This report delineates leading suppliers for emtricitabine, rilpivirine, and TDF, analyzing their manufacturing footprint, regulatory status, and market influence.

1. Emtricitabine Suppliers

Overview

Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor (NRTI) integral in HIV treatment, often formulated with tenofovir and efavirenz or rilpivirine.

Key Suppliers

A. Zhejiang Huahai Pharmaceutical Co., Ltd. (China)

Manufacturing Capabilities: Produces generic emtricitabine API meeting WHO prequalification standards.
Market Presence: Supplies to global generics companies; actively exports to developing markets.
Regulatory Status: Approved by multiple stringent regulatory authorities (SRAs), including the WHO-Prequalified list.

B. Dr. Reddy’s Laboratories (India)

Production: Manufactures both API and finished dosage forms.
Reputation: Known for high-quality APIs compliant with international standards and a significant player in supplying affordable emtricitabine generics globally.
Compliance: Holds approvals from USFDA, EMA, and other SRAs.

C. Mylan Pharmaceuticals (United States/Global)

Market Role: Offers both APIs and finished formulations.
Distribution: Serves a broad international market, including low- and middle-income countries.

D. Sun Pharmaceutical Industries Ltd. (India)

Production: Engages in synthesis of emtricitabine API.
Market Presence: Supplies to multiple markets with WHO prequalification.

2. Rilpivirine Suppliers

Overview

Rilpivirine (RPV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used in combination ART, notably as part of the Complera and Odefsey formulations.

Key Suppliers

A. Janssen Pharmaceuticals (Johnson & Johnson)

Role: Original developer and patent holder.
Supply Chain: Manufactures both API and finished drug products domestically in the US and internationally through licensing partnerships.
Market Reach: Limited for raw API supply but vital for proprietary formulations.

B. Dr. Reddy’s Laboratories (India)

API Synthesis: Manufactures RPV API at scale, adhering to cGMP standards.
Regulatory Standing: Approvals include USFDA and WHO prequalification, facilitating distribution in multiple markets.

C. Hetero Labs Ltd. (India)

Current Status: Engaged in RPV API manufacturing, with regulatory approvals in key jurisdictions.
Market Penetration: Growing presence through licensing and generic formulation supplies.

D. Apotex Inc. (Canada)

Market Role: Supplies RPV APIs and formulations with compliance to international standards.
Distribution Channels: Focused on North America and emerging markets.

3. Tenofovir Disoproxil Fumarate (TDF) Suppliers

Overview

TDF is a nucleotide reverse transcriptase inhibitor (NtRTI), foundational in many first-line HIV therapies, often combined with emtricitabine and rilpivirine.

Key Suppliers

A. Gilead Sciences (United States)

Original Manufacturer: Patented provider of TDF, with proprietary manufacturing processes.
Market Position: Dominant supplier; however, patent expirations have opened avenues for generic manufacturing.

B. Teva Pharmaceutical Industries (Israel)

Generic Producer: One of the largest generic API manufacturers globally.
Regulatory Approvals: Holds multiple approvals for TDF API, including WHO prequalification.

C. Hetero Labs Ltd. (India)

Production Capacity: Offers TDF API at large scale, meeting international quality standards.
Market Footprint: Major supplier to global markets, especially Africa and Asia.

D. Sun Pharmaceutical Industries Ltd.

Role: Manufactures TDF API with regulatory approvals facilitating diverse geographic distribution.

E. Cipla Ltd. (India)

Generics: Produces TDF API and formulations; often partnered with Gilead under licensing agreements or through generics manufacturing.

Regulatory and Market Implications

The supply landscape for these APIs is heavily influenced by patent statuses, regulatory approvals, and manufacturing capacities. Gilead retains exclusivity over TDF's patent rights in certain jurisdictions, but generic manufacturers have gained approval post-patent expiry, notably in India and other emerging markets, complicating the supply chain dynamics.

India and China dominate the API manufacturing market for emtricitabine, rilpivirine, and TDF owing to higher production volumes and cost advantages. WHO prequalification and USFDA approvals serve as critical benchmarks for quality assurance, affecting market access.

Manufacturers should prioritize partnerships with suppliers holding valid regulatory approvals, transparent supply chains, and sustained production capacity. This is essential for maintaining uninterrupted access, especially in low-resource settings where affordability and quality are paramount.

Conclusion

The global supply of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate hinges on a core group of manufacturers primarily based in India and China, with strategic contributions from Western pharmaceutical companies. Ensuring supply chain resilience requires ongoing regulatory oversight, investment in manufacturing capacity, and fostering partnerships that prioritize quality and compliance.

Key Takeaways

India and China are central to the API supply chain, offering cost-effective manufacturing capacities for emtricitabine, rilpivirine, and TDF.
Regulatory approvals (WHO, USFDA, EMA) are critical for global distribution, particularly in resource-limited settings.
Patent expirations have expanded the landscape for generic API manufacturers, increasing competition but necessitating vigilant quality assurance.
Supply chain security depends on diversification of suppliers and strong regulatory oversight to prevent shortages.
Partnerships with approved manufacturers ensure consistent access to high-quality APIs, critical for effective HIV treatment programs.

FAQs

Q1: What are the main countries producing generic emtricitabine?
A: India and China are leading producers of generic emtricitabine, with companies like Dr. Reddy’s and Zhejiang Huahai Pharmaceutical establishing substantial manufacturing capacity.

Q2: Who are the key suppliers of rilpivirine?
A: Major suppliers include Dr. Reddy’s Laboratories, Hetero Labs, and Apotex, with original development by Janssen Pharmaceuticals primarily controlling proprietary formulations.

Q3: Is tenofovir disoproxil fumarate still under patent protection?
A: Patent expiration varies by jurisdiction; in many countries, patents have expired, enabling generic manufacturing, notably in India, which has expanded global access.

Q4: How does WHO prequalification influence supplier credibility?
A: WHO prequalification certifies that APIs and formulations meet global quality standards, facilitating procurement by UN agencies and national procurement agencies.

Q5: What are the risks associated with API supply concentration?
A: Dependence on a limited number of suppliers can lead to supply shortages, quality issues, and price volatility. Diversification and supply chain resilience are vital.

Sources

[1] WHO List of Prequalified Medicinal Products (2022)
[2] U.S. Food and Drug Administration (FDA) Database
[3] Company Annual Reports and Regulatory Filings
[4] Market Intelligence Reports on API Manufacturing

Note: Specific company supply details are derived from publicly available regulatory filings and market reports as of 2023.

Suppliers and packagers for EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE